Pharma Stocks

Takeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervalued

Takeda Pharmaceutical (TSE:4502) is back in focus after releasing new Phase 3 data for its oral TYK2 inhibitor zasocitinib in…

Read More »

Eton Pharmaceuticals (ETON) Stock Looks Overvalued Even After Recent Wins

Eton Pharmaceuticals has turned heads with a very large 3 year return and a fresh 52 week run, yet its…

Read More »

Does Shionogi’s Pediatric Fetroja sNDA Shift the Bull Case For Shionogi (TSE:4507)?

Shionogi recently announced that the U.S. FDA has accepted a Supplemental New Drug Application for Fetroja (cefiderocol) to treat pediatric…

Read More »

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals in an all-stock transaction. Concurrent with the closing, Jasper raised approximately $132…

Read More »

Does Zasocitinib’s Phase 3 Success in Hard-to-Treat Psoriasis Areas Change The Bull Case For Takeda Pharmaceutical (TSE:4502)?

In July 2026, Takeda reported positive Phase 3 results for its oral TYK2 inhibitor zasocitinib in adults with moderate-to-severe plaque…

Read More »

Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating?

Amneal Pharmaceuticals (AMRX) is back in focus after a recent review highlighted strong long term shareholder returns, alongside slower projected…

Read More »

Ligand Pharmaceuticals (LGND) Closes XOMA Deal, Is The Stock Still Below Fair Value?

Ligand Pharmaceuticals (LGND) has completed its approximately US$739 million cash acquisition of XOMA Royalty Corporation, adding seven commercial products and…

Read More »

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

Determining where to allocate capital in the healthcare sector often involves choosing between established stability and aggressive growth. Both Johnson…

Read More »

Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival. J&J said it aims to…

Read More »

Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.…

Read More »